MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer

Annals of Oncology

Volumn 19, Issue 4, 2008, Pages 669-674

  Eralp, Y ^a   Derin, D ^a   Ozluk, Y ^b   Yavuz, E ^b   Guney, N ^a   Saip, P ^a   Muslumanoglu, M ^b   Igci, A ^b   Kucucuk S ^a   Dincer, M ^a   Aydiner, A ^a   Topuz, E ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chemo resistance; EGFR; MAPK; Prognosis; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE INTERVAL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECURRENCE RISK;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 41549153733     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm522     Document Type: Article

References (30)

1. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet 2007; 8: 235-244.
2. Korsching E, Päckeisen J, Agelopoulos K et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002; 82: 1525-1533.
3. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
4. Foulkes WD, Steffansson IM, Chappuis PO et al. Germline BRGA-1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-1489.
5. Santen RJ, Song RX, McPherson R et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002; 80: 239-256.
6. McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279.
7. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007; 16: 104-107.
8. Hafty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis In conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657.
9. Kim MJ, Ro JYR, Ahn SH et al. Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone-receptor and Her-2/neu-overexpressing phenotypes. Hum Pathol 2006; 37: 1217-1226.
10. Rakha EA, EI-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
11. Van de Rijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991-1996.
12. Banarjee S, Reiss-Filho JS, Ashley S et al. Basal-like breast carcinomas: Clinical outcome and responqe to chemotherapy. J Clin Pathol 2006; 59: 729-735.
13. Livasy, CA, Karaca G, Nanda R et al. Phenotypic evaluation of Ae basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271.
14. Osbourne CR, Kannan L, Asfaq R et al. Clinical and pathological classification of basal-like breast cancer. Breast Cancer Res Treat 2005; 94 (Suppl 1): S118.
15. Rodriguez-Pinilla SM, Sarrio D, Honrado E et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006: 12: 1533-1539.
16. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
17. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418.
18. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
19. Jeng MH, Shupnik MA, Bender TP et al. Estrogen receptor expression and function in long-term estrogen deprived human breast cancer cells. Endocrinology 1998; 139: 4164-4174.
20. Shim WS, Conaway M, Masamura S et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen-deprived human breast cancer cells in vivo. Endocrinology 2000; 141: 396-405.
21. Salh B, Marotta C, Mattewson C et al. Investigation of the MEK-MAP kinase-Rsk pathway in human breast cancer. Anticanser Res 1999; 19: 731-740.
22. Moyano JV, Evans JR, Chen F et al. Alpha-B-crystallin is a novel onco-protein that predicts poor clinical outoome in breast cancer. J Clin Invest 2006; 116: 261-270.
23. Esteva FJ, Hortobagyi GN, Sphin AA et al. Expression of erbB/HER receptors, heregulln and P38 in primary breast cancer using immunohistochemistry. Pathol Oncol Res 2001; 7: 171-177.
24. Esteva FJ, Sahin AA, Smith TL et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and Her-2 expression in lymph node-positive breast carcinoma. Cancer 2004; 100: 499-506.
25. Oh AS, Lorant LA, Holloway JN et al. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001; 15: 1344-1359.
26. Creighton CJ, Hilger AM, Murthy S et al. Activation of mitogen-activated protein (MAP) kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor negative human breast tumors. Cancer Res 2006; 66: 3903-3911.
27. Gee JMW, Robertson JFR, Ellis IO, Nicholson RI. Phosphorylation of ERK1/ 2 mitogen-activated protein (MAP) kinase is associated with poor response to antihormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247-254.
28. Mueller H, Flury N, Eppenberger-Castori S et al. Potential prognostic value of mitogen-activated protein (MAP) kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000; 89: 384-388.
29. von Lintig FC, Drellinger AD, Varki NM et al. Ras activation in human breast cancer. Breast Cancer Res Treat 2000; 62: 51-62.
30. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein (MAP) kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007; 67: 4459-4466.